Sensorium is a clinical-stage biotechnology company focused on developing CNS treatments derived from natural compounds. The company utilizes its proprietary SensAI platform, which integrates chemistry, neuroscience, and pharmacology across over 50 million data relationships to systematically identify therapeutic patterns. This approach has yielded several differentiated drug candidates, including SENS-01, a precision therapy currently in clinical trials for anxiety disorders.
Funding
$39.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
R6TCFounders
Product
Problem
Mental health and neurological disorders represent a growing unmet medical need. Current treatments often lack efficacy or have significant side effects, highlighting the need for novel therapeutic approaches. Traditional drug discovery methods can be slow and inefficient, particularly when dealing with the complexity of the human brain.
Solution
Sensorium Therapeutics is developing FDA-approved psychoactive medicines by integrating chemistry, neuroscience, and machine learning through its Biodynamic Discovery Platform™ (BDP). The platform aims to de-risk the drug development process by identifying and advancing safe and effective neuroactive compounds inspired by natural substances. This approach allows Sensorium to address unmet medical needs in mental health and neurological disorders with innovative treatments. The company focuses on embracing the biological complexity of the human brain to create breakthrough medicines.
Target Audience
The primary target audience includes individuals suffering from mental health and neurological disorders, as well as healthcare providers seeking innovative and effective treatment options.
Features
- Biodynamic Discovery Platform™ (BDP) integrates chemistry, neuroscience, and machine learning.
- Focus on identifying and developing neuroactive compounds inspired by natural substances.
- Aims to de-risk the drug development process for mental health and neurological disorders.
- Targets unmet medical needs in anxiety and epilepsy.